Dr. Aung Myo
Tessa Therapeutics, Singapore
Biography
A Medical Oncologist, with a broad and deep range of experience in pharmaceutical industry for both clinical development and medical affairs in oncology area. A Lead regional team of clinical and medical affairs for cancer immunotherapy working with 14 countries across Asia Pacific.
A Regional Leader for clinical development of Cancer Immunotherapy trials, ranging from tumor maker studies to various phases of clinical trials and investigator-sponsored studies in the Asia Pacific. Experienced in global clinical development as the leader for Esophageal, Gastric cancers and HCC. Involved in IND application, safety and compliance.
A leader of regional medical affairs for Oncology medical affairs who set up and lead Oncology Medical Affairs Organization in Asia Pacific and formulate medical affairs strategies and action plans for Anti-PD1 immunotherapy. Lead the new product introduction team (commercial, regulatory, market access teams) for launch preparation, and provide medical support for launch and post-launch activities. Organize regional advisory boards and medical education activities and has a peer-to-peer relationship with oncology experts in the region.
A Regional Leader for clinical development of Cancer Immunotherapy trials, ranging from tumor maker studies to various phases of clinical trials and investigator-sponsored studies in the Asia Pacific. Experienced in global clinical development as the leader for Esophageal, Gastric cancers and HCC. Involved in IND application, safety and compliance.
A leader of regional medical affairs for Oncology medical affairs who set up and lead Oncology Medical Affairs Organization in Asia Pacific and formulate medical affairs strategies and action plans for Anti-PD1 immunotherapy. Lead the new product introduction team (commercial, regulatory, market access teams) for launch preparation, and provide medical support for launch and post-launch activities. Organize regional advisory boards and medical education activities and has a peer-to-peer relationship with oncology experts in the region.